Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9634847 | 0.86 | L3MBTL1 (0.50) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL11458252 | 0.82 | ALDH1A1 (0.44) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL28941447 | 0.80 | SRC (0.52) | SRCL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL31332475 | 0.80 | SRC (0.52) | SRCL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL28708046 | 0.78 | CA4 (0.42) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL4594032 | 0.78 | CA4 (0.42) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL3065840 | 0.77 | SRC (0.43) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL305506 | 0.77 | SRC (0.54) | SRCL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL428879 | 0.77 | SRC (0.54) | SRCL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL9856545 | 0.77 | SRC (0.43) | SRCL3MBTL1TDP1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118292297-B | Washable flame retardant applied to filter material and application method thereof | 东莞市三威新材料科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118292297-A | Washable flame retardant applied to filter material and application method thereof | 东莞市三威新材料科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-118292297-B | Washable flame retardant applied to filter material and application method thereof | 东莞市三威新材料科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118292297-B | Washable flame retardant applied to filter material and application method thereof | 东莞市三威新材料科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118292297-A | Washable flame retardant applied to filter material and application method thereof | 东莞市三威新材料科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118292297-A | Washable flame retardant applied to filter material and application method thereof | 东莞市三威新材料科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-2984097-B1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9447132-B2 | Highly active nucleoside derivative for the treatment of HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2984098-A2 | DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV | Achillion Pharmaceuticals, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2984097-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | Achillion Pharmaceuticals, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20140309164-A1 | DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309189-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014169280-A2 | DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014169278-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| CN-101302327-B | Halogen-free fire-resistant epoxy resin composition, film and copper clad laminate | GUANGKE INDUSTRY CORP | 2011-05-04 | — | — | CN | disclosed |
| CN-101302327-A | Halogen-free fire-resistant epoxy resin composition, film and copper clad laminate | GUANGKE INDUSTRY CORP (CN) | 2008-11-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | SRC 3812/4885L3MBTL1 1370/4885TDP1 1464/4885 |
| US-20140309189-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | SLC28A1, SLC28A2, NUDT1 | SRC 2283/4885L3MBTL1 3650/4885TDP1 1359/4885 |
| US-20140309164-A1 | DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV | PNP, SLC29A1, SLC28A1 | SRC 3411/4885L3MBTL1 1041/4885TDP1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.